{"metadata":{"total_drugs_analyzed":10,"max_results_per_drug":50,"max_pmids_analyzed_per_drug":10,"max_drugs_limit":10,"generated_on":"2025-06-30T16:26:30.354","description":"Comprehensive PubMed drug-disease association analysis"},"results":[{"indication":"For the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.","drug_name":"Acenocoumarol","pmids_analyzed":["40546510","40453154","40390869","40389391","40230696","40220367","40199158","40198642","40178736","40129850"],"count":1845,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[],"pmid":"40546510","title":"Long-Term Outcomes of Valve Replacement With Mechanical Prosthesis in Patients With Valvular Heart Disease: A Single-Center Retrospective Study."},{"mesh_descriptors":[],"pmid":"40453154","title":"Obstructive Pharyngo-Laryngeal Hematoma Complicating Oral Anticoagulation: Case Report."},{"mesh_descriptors":[],"pmid":"40390869","title":"Quality of vitamin K antagonist treatment during the last year of life."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["statistics &amp; numerical data"],"descriptor":"International Normalized Ratio"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"Vitamin K"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Anticoagulants"},{"qualifiers":["epidemiology"],"descriptor":"Netherlands"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["statistics &amp; numerical data"],"descriptor":"Drug Prescriptions"},{"qualifiers":["methods"],"descriptor":"Pharmacoepidemiology"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"}],"pmid":"40389391","title":"Determining Drug Exposure Based on Medication Dispensing Data: A Validation Study of Vitamin K Antagonist Treatment Episodes Against INR Records."},{"mesh_descriptors":[],"pmid":"40230696","title":"Corrigendum: A pharmacogenetically-guided acenocoumarol dosing algorithm for Chilean patients: a discovery cohort study."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects","administration &amp; dosage"],"descriptor":"Acenocoumarol"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["adverse effects","administration &amp; dosage"],"descriptor":"Anticoagulants"},{"qualifiers":[],"descriptor":"Risk Factors"},{"qualifiers":["epidemiology"],"descriptor":"Drug Overdose"},{"qualifiers":["chemically induced","epidemiology"],"descriptor":"Hemorrhage"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":[],"descriptor":"Tunisia"},{"qualifiers":["drug therapy"],"descriptor":"Atrial Fibrillation"},{"qualifiers":[],"descriptor":"International Normalized Ratio"},{"qualifiers":["drug therapy"],"descriptor":"Venous Thromboembolism"},{"qualifiers":[],"descriptor":"Retrospective Studies"}],"pmid":"40220367","title":"[Not Available]."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["metabolism"],"descriptor":"Cytochrome P-450 Enzyme System"},{"qualifiers":["physiology"],"descriptor":"Metabolic Clearance Rate"},{"qualifiers":["metabolism","enzymology"],"descriptor":"Microsomes, Liver"},{"qualifiers":["metabolism"],"descriptor":"Isoenzymes"},{"qualifiers":["metabolism"],"descriptor":"Liver"},{"qualifiers":["metabolism"],"descriptor":"Pharmaceutical Preparations"},{"qualifiers":[],"descriptor":"Male"}],"pmid":"40199158","title":"In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["chemistry"],"descriptor":"Ginkgo biloba"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["chemically induced","epidemiology"],"descriptor":"Hemorrhage"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["adverse effects","pharmacology"],"descriptor":"Plant Extracts"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":["adverse effects"],"descriptor":"Anticoagulants"},{"qualifiers":[],"descriptor":"Retrospective Studies"},{"qualifiers":["drug effects"],"descriptor":"Blood Coagulation"},{"qualifiers":[],"descriptor":"Herb-Drug Interactions"},{"qualifiers":[],"descriptor":"Drug Interactions"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":["adverse effects"],"descriptor":"Platelet Aggregation Inhibitors"},{"qualifiers":[],"descriptor":"Risk Factors"},{"qualifiers":["adverse effects"],"descriptor":"Anti-Inflammatory Agents, Non-Steroidal"},{"qualifiers":[],"descriptor":"Ginkgo Extract"}],"pmid":"40198642","title":"Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Retrospective Studies"},{"qualifiers":["antagonists &amp; inhibitors","therapeutic use"],"descriptor":"Vitamin K"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["therapeutic use","pharmacology"],"descriptor":"Anticoagulants"},{"qualifiers":["drug therapy"],"descriptor":"Thrombosis"},{"qualifiers":["physiopathology","drug effects"],"descriptor":"Heart Ventricles"},{"qualifiers":[],"descriptor":"Cohort Studies"}],"pmid":"40178736","title":"Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study."},{"mesh_descriptors":[],"pmid":"40129850","title":"Progressive coronary aneurysms in Kawasaki disease: A case report and long-term follow-up."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":0,"matched_diseases":[],"diseases_with_associations":0,"total_mesh_terms":64,"total_publications_analyzed":10},"disease_associations":{}},"pmids":["40546510","40453154","40390869","40389391","40230696","40220367","40199158","40198642","40178736","40129850","40126224","40087557","39971633","39941667","39930857","39918252","39893780","39793412","39770500","39585298","39479767","39439867","39431840","39308615","39252452","39202728","39185811","39154023","39126897","39076884","38849073","38716521","38681325","38580096","38500896","38264177","38056770","37865961","37791549","37704534","37505934","37489950","37385211","37371528","37330507","37321159","37292568","37273146","37193442","37183637"]},{"indication":"For use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I. It is also used in follow-up imaging for chemoembolization.","drug_name":"Ethiodized oil","pmids_analyzed":["40514211","40472720","40468032","40409614","40394522","40389472","40338615","40292366","40226387","40089104"],"count":1481,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapy","etiology","diagnostic imaging"],"descriptor":"Chylous Ascites"},{"qualifiers":["methods"],"descriptor":"Embolization, Therapeutic"},{"qualifiers":["adverse effects"],"descriptor":"Nephrectomy"},{"qualifiers":["surgery"],"descriptor":"Kidney Neoplasms"},{"qualifiers":[],"descriptor":"Lymphography"},{"qualifiers":["surgery"],"descriptor":"Carcinoma, Renal Cell"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Ethiodized Oil"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Lymphatic Vessels"},{"qualifiers":["therapy"],"descriptor":"Postoperative Complications"}],"pmid":"40514211","title":"Percutaneous lymphatic duct embolisation in postnephrectomy chylous ascites."},{"mesh_descriptors":[],"pmid":"40472720","title":"Ice ball size and temperature change during cryoablation in a lard and an ethiodized-oil tissue phantom."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":["therapy","pathology"],"descriptor":"Stomach Neoplasms"},{"qualifiers":[],"descriptor":"Retrospective Studies"},{"qualifiers":["methods"],"descriptor":"Chemoembolization, Therapeutic"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Ethiodized Oil"},{"qualifiers":[],"descriptor":"Infusions, Intra-Arterial"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["pathology"],"descriptor":"Gastric Fundus"},{"qualifiers":["pathology"],"descriptor":"Cardia"},{"qualifiers":["therapeutic use","administration &amp; dosage"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":[],"descriptor":"Combined Modality Therapy"},{"qualifiers":[],"descriptor":"Aged, 80 and over"}],"pmid":"40468032","title":"Transcatheter arterial infusion chemotherapy combined with lipiodol chemoembolization for advanced gastric fundus and cardia cancer with obstruction."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["chemistry","pharmacology"],"descriptor":"Ethiodized Oil"},{"qualifiers":["chemistry"],"descriptor":"Nanoparticles"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":["methods"],"descriptor":"Embolization, Therapeutic"},{"qualifiers":["therapy","blood supply","pathology"],"descriptor":"Neoplasms"},{"qualifiers":["chemistry"],"descriptor":"Serum Albumin, Human"},{"qualifiers":[],"descriptor":"Cell Line, Tumor"}],"pmid":"40409614","title":"Protein-based embolic agent loaded with ethiodized oil for targeted tumor vascular embolization."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapy","complications","pathology"],"descriptor":"Carcinoma, Hepatocellular"},{"qualifiers":["therapy","complications","pathology"],"descriptor":"Liver Neoplasms"},{"qualifiers":["methods","instrumentation"],"descriptor":"Chemoembolization, Therapeutic"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Sorafenib"},{"qualifiers":["therapeutic use","administration &amp; dosage"],"descriptor":"Phenylurea Compounds"},{"qualifiers":["therapy","etiology","complications"],"descriptor":"Arteriovenous Fistula"},{"qualifiers":[],"descriptor":"Hepatic Artery"},{"qualifiers":["abnormalities"],"descriptor":"Portal Vein"},{"qualifiers":[],"descriptor":"Gelatin Sponge, Absorbable"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Quinolines"},{"qualifiers":["therapeutic use","administration &amp; dosage"],"descriptor":"Antineoplastic Agents"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":[],"descriptor":"Combined Modality Therapy"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Ethiodized Oil"}],"pmid":"40394522","title":"Clinical efficacy of TACE using coil or gelatin sponge combined with targeted therapy in the treatment of giant hepatocellular carcinoma with arterioportal fistulas."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Swine"},{"qualifiers":["pathology","diagnostic imaging"],"descriptor":"Liver"},{"qualifiers":[],"descriptor":"Tomography, X-Ray Computed"},{"qualifiers":[],"descriptor":"Pilot Projects"},{"qualifiers":["methods"],"descriptor":"Embolization, Therapeutic"},{"qualifiers":["therapy","pathology","diagnostic imaging"],"descriptor":"Liver Neoplasms"},{"qualifiers":[],"descriptor":"Disease Models, Animal"},{"qualifiers":["methods"],"descriptor":"Chemoembolization, Therapeutic"},{"qualifiers":["chemistry"],"descriptor":"Ethiodized Oil"}],"pmid":"40389472","title":"A fundamentally new direction in embolization using reactive chemistry in a swine model."},{"mesh_descriptors":[{"qualifiers":["chemistry","therapeutic use","pharmacology"],"descriptor":"Iodine Radioisotopes"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["drug effects","radiation effects"],"descriptor":"Ferroptosis"},{"qualifiers":["methods"],"descriptor":"Embolization, Therapeutic"},{"qualifiers":["pathology","therapy","radiotherapy"],"descriptor":"Liver Neoplasms"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":["chemistry","pharmacology"],"descriptor":"Ethiodized Oil"},{"qualifiers":["chemistry"],"descriptor":"Iron"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Cell Line, Tumor"},{"qualifiers":["drug effects"],"descriptor":"Apoptosis"},{"qualifiers":["chemistry"],"descriptor":"Nanoparticles"},{"qualifiers":[],"descriptor":"Rats"}],"pmid":"40338615","title":"Turning Waste into Treasure: Radiation Byproduct-Induced Fe(III)/Fe(II) Conversion for Efficient Ferroptosis to Improve Iodine-131-Based Transarterial Radioembolization for Liver Tumors."},{"mesh_descriptors":[],"pmid":"40292366","title":"A novel method of using indocyanine green fluorescence technique for nephron-sparing surgery."},{"mesh_descriptors":[],"pmid":"40226387","title":"Transarterial Chemoembolization: A Consistent and Continuously Evolving Therapy for Hepatocellular Carcinoma."},{"mesh_descriptors":[],"pmid":"40089104","title":"Resolution of Postoperative Liver Lymphatic Leakage following Ethiodized Oil Injection without Embolization."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":1,"matched_diseases":["Chylous Ascites"],"diseases_with_associations":1,"total_mesh_terms":79,"total_publications_analyzed":10},"disease_associations":{"Chylous Ascites":[{"pmid":"40514211","title":"Percutaneous lymphatic duct embolisation in postnephrectomy chylous ascites.","qualifiers":["therapy","etiology","diagnostic imaging"]}]}},"pmids":["40514211","40472720","40468032","40409614","40394522","40389472","40338615","40292366","40226387","40089104","40064655","40058580","40052319","40018282","39985643","39962141","39884351","39880038","39863284","39848326","39843295","39831816","39728904","39709852","39680010","39656891","39654272","39611766","39610425","39538994","39531441","39498531","39487694","39428064","39406873","39393518","39370462","39343573","39340741","39287280","39278213","39243201","39227527","39227519","39160360","39154241","39153723","39152197","39138591","39118578"]},{"indication":"Sulfathiazole is effective against a wide range of gram positive and gram negative pathogenic microorganisms. Although no longer used in humans, it is used in cattle.","drug_name":"Sulfathiazole","pmids_analyzed":["40382925","40315774","40120291","40049875","39673945","39505039","39461293","39362166","39310134","39265847"],"count":1258,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":["chemistry"],"descriptor":"Lakes"},{"qualifiers":["chemistry"],"descriptor":"Geologic Sediments"},{"qualifiers":[],"descriptor":"Molecular Weight"},{"qualifiers":["chemistry"],"descriptor":"Sulfathiazole"},{"qualifiers":["chemistry"],"descriptor":"Sulfadiazine"},{"qualifiers":["chemistry"],"descriptor":"Sulfathiazoles"},{"qualifiers":["chemistry"],"descriptor":"Water Pollutants, Chemical"}],"pmid":"40382925","title":"Influence of the source and molecular weights on sulfathiazole/sulfadiazine binding in sedimentary dissolved organic matter."},{"mesh_descriptors":[{"qualifiers":["methods"],"descriptor":"Chromatography, Reverse-Phase"},{"qualifiers":["chemistry"],"descriptor":"Formates"},{"qualifiers":["analysis","chemistry","isolation &amp; purification"],"descriptor":"Hydrocarbons, Aromatic"},{"qualifiers":["methods"],"descriptor":"Green Chemistry Technology"},{"qualifiers":["analysis","chemistry","isolation &amp; purification"],"descriptor":"Polycyclic Aromatic Hydrocarbons"},{"qualifiers":["chemistry"],"descriptor":"Solvents"},{"qualifiers":["methods"],"descriptor":"Chromatography, High Pressure Liquid"},{"qualifiers":[],"descriptor":"Solubility"}],"pmid":"40315774","title":"Dimethyl carbonate as a green mobile phase modifier for reversed phase liquid chromatography of polar aromatic and polyaromatic hydrocarbons."},{"mesh_descriptors":[{"qualifiers":["chemistry"],"descriptor":"Liposomes"},{"qualifiers":["analysis","isolation &amp; purification"],"descriptor":"Sulfonamides"},{"qualifiers":["analysis","isolation &amp; purification"],"descriptor":"Anti-Bacterial Agents"},{"qualifiers":["instrumentation","methods"],"descriptor":"Immunoassay"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Biosensing Techniques"},{"qualifiers":[],"descriptor":"Lab-On-A-Chip Devices"},{"qualifiers":[],"descriptor":"Limit of Detection"},{"qualifiers":["chemistry"],"descriptor":"Milk"},{"qualifiers":[],"descriptor":"Chickens"},{"qualifiers":["chemistry"],"descriptor":"Metal-Organic Frameworks"},{"qualifiers":[],"descriptor":"Porphyrins"}],"pmid":"40120291","title":"Bi-model detection of sulfonamide antibiotics using a microfluidic chip-lateral flow immunoassay based on liposome-modified PCN-222."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Catalysis"},{"qualifiers":["chemistry","analysis"],"descriptor":"Water Pollutants, Chemical"},{"qualifiers":["chemistry"],"descriptor":"Hydrogen Peroxide"},{"qualifiers":["chemistry"],"descriptor":"Iron"},{"qualifiers":[],"descriptor":"Oxidation-Reduction"},{"qualifiers":[],"descriptor":"Models, Chemical"},{"qualifiers":[],"descriptor":"Electrochemical Techniques"},{"qualifiers":["chemistry"],"descriptor":"Sulfathiazoles"},{"qualifiers":["chemistry"],"descriptor":"Sulfathiazole"},{"qualifiers":[],"descriptor":"Nitrites"},{"qualifiers":[],"descriptor":"Transition Elements"}],"pmid":"40049875","title":"FeCN/MXene as novel heterogeneous electro-Fenton catalysts for the degradation of sulfathiazole: Performance and mechanism investigation."},{"mesh_descriptors":[],"pmid":"39673945","title":"Substituent structure variances alter degradation pathways of sulfonamides in UV/PAA system: Insights from intermediates, ROS, and DFT calculations."},{"mesh_descriptors":[{"qualifiers":["toxicity","chemistry"],"descriptor":"Sulfamethoxazole"},{"qualifiers":["toxicity","chemistry"],"descriptor":"Water Pollutants, Chemical"},{"qualifiers":["methods"],"descriptor":"Waste Disposal, Fluid"},{"qualifiers":["chemistry"],"descriptor":"Wastewater"},{"qualifiers":["metabolism"],"descriptor":"Reactive Oxygen Species"}],"pmid":"39505039","title":"Degradation of sulfamethoxazole in a falling film dielectric barrier discharge system: Performance, mechanism and toxicity evaluation."},{"mesh_descriptors":[{"qualifiers":["metabolism"],"descriptor":"Chlorella"},{"qualifiers":[],"descriptor":"Biotransformation"},{"qualifiers":["metabolism"],"descriptor":"Water Pollutants, Chemical"},{"qualifiers":[],"descriptor":"Biodegradation, Environmental"},{"qualifiers":["metabolism"],"descriptor":"Sulfathiazole"},{"qualifiers":["metabolism"],"descriptor":"Sulfathiazoles"},{"qualifiers":["metabolism"],"descriptor":"Microalgae"}],"pmid":"39461293","title":"Molecular insights into biological transformation mechanism of sulfathiazole by Chlorella sorokiniana: Deciphering the uptake, translocation, and biotransformation."},{"mesh_descriptors":[{"qualifiers":["chemistry"],"descriptor":"Copper"},{"qualifiers":["chemistry"],"descriptor":"Sulfonamides"},{"qualifiers":["chemistry"],"descriptor":"Anti-Bacterial Agents"},{"qualifiers":[],"descriptor":"Oxidation-Reduction"},{"qualifiers":["chemistry"],"descriptor":"Water Pollutants, Chemical"}],"pmid":"39362166","title":"Insight into efficient degradation of pentacyclic and hexacyclic sulfonamide antibiotics by synthetic trivalent copper: Performance and mechanism."},{"mesh_descriptors":[],"pmid":"39310134","title":"Atomistic Analysis of Sulphonamides as a Microbial Influenced Corrosion (MIC) Inhibitor."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Micelles"},{"qualifiers":["chemistry"],"descriptor":"Surface-Active Agents"},{"qualifiers":["chemistry"],"descriptor":"Pharmaceutical Preparations"}],"pmid":"39265847","title":"Interaction of drug molecules with surfactants below (Benesi-Hildebrand equation) and above the critical micelle concentration (Kawamura equation)."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":0,"matched_diseases":[],"diseases_with_associations":0,"total_mesh_terms":58,"total_publications_analyzed":10},"disease_associations":{}},"pmids":["40382925","40315774","40120291","40049875","39673945","39505039","39461293","39362166","39310134","39265847","39208733","39203054","39173382","39073366","38910173","38905827","38852344","38849528","38744394","38670426","38647963","38631420","38581981","38556151","38493620","38391560","38344834","38307331","38290656","38150758","38117940","38109839","38075833","38066229","38056266","38027349","37917269","37906732","37843710","37819078","37722535","37683435","37601915","37544526","37513261","37469159","37402503","37392966","37390778","37277000"]},{"indication":"For treatment and management of Parkinson's disease.","drug_name":"Cycrimine","pmids_analyzed":["32108589","8938597","8649435","2573609","862878","1267542","13575361","13477721","14371520","13221464"],"count":10,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Cell Line"},{"qualifiers":["drug effects"],"descriptor":"Cell Survival"},{"qualifiers":[],"descriptor":"Computer Simulation"},{"qualifiers":[],"descriptor":"Dogs"},{"qualifiers":[],"descriptor":"Drug Repositioning"},{"qualifiers":["drug effects"],"descriptor":"Influenza A Virus, H1N1 Subtype"},{"qualifiers":["drug effects"],"descriptor":"Influenza A Virus, H3N2 Subtype"},{"qualifiers":["pharmacology"],"descriptor":"Piperidines"}],"pmid":"32108589","title":"In vitro anti-influenza activity of in silico repurposed candidate drug cycrimine."},{"mesh_descriptors":[{"qualifiers":["immunology","metabolism"],"descriptor":"2,4-Dinitrophenol"},{"qualifiers":[],"descriptor":"Algorithms"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["chemistry","immunology","metabolism"],"descriptor":"Antibodies, Monoclonal"},{"qualifiers":[],"descriptor":"Antibody Affinity"},{"qualifiers":[],"descriptor":"Antibody Specificity"},{"qualifiers":[],"descriptor":"Antigen-Antibody Reactions"},{"qualifiers":[],"descriptor":"Binding Sites, Antibody"},{"qualifiers":[],"descriptor":"Computer Simulation"},{"qualifiers":[],"descriptor":"Haptens"},{"qualifiers":["chemistry","immunology","metabolism"],"descriptor":"Immunoglobulin E"},{"qualifiers":[],"descriptor":"Ligands"},{"qualifiers":[],"descriptor":"Macromolecular Substances"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":[],"descriptor":"Models, Immunological"},{"qualifiers":[],"descriptor":"Models, Molecular"},{"qualifiers":[],"descriptor":"Protein Conformation"}],"pmid":"8938597","title":"Prediction of IgE(Lb4)-ligand complex structures by automated docking."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Amino Acid Sequence"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["chemistry","genetics","metabolism"],"descriptor":"Antibodies, Monoclonal"},{"qualifiers":[],"descriptor":"Binding Sites"},{"qualifiers":[],"descriptor":"Binding, Competitive"},{"qualifiers":[],"descriptor":"Computer Simulation"},{"qualifiers":["immunology","metabolism"],"descriptor":"Dinitrobenzenes"},{"qualifiers":[],"descriptor":"Enzyme-Linked Immunosorbent Assay"},{"qualifiers":[],"descriptor":"Haptens"},{"qualifiers":["chemistry","genetics","metabolism"],"descriptor":"Immunoglobulin E"},{"qualifiers":[],"descriptor":"Ligands"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":[],"descriptor":"Models, Molecular"},{"qualifiers":[],"descriptor":"Molecular Sequence Data"},{"qualifiers":[],"descriptor":"Molecular Structure"},{"qualifiers":[],"descriptor":"Monte Carlo Method"}],"pmid":"8649435","title":"Heteroligation of a mouse monoclonal IgE antibody (La2) with small molecules, analysed by computer-aided automated docking."},{"mesh_descriptors":[{"qualifiers":["pharmacology"],"descriptor":"Antipsychotic Agents"},{"qualifiers":[],"descriptor":"Chromatography, Gas"},{"qualifiers":[],"descriptor":"False Positive Reactions"},{"qualifiers":[],"descriptor":"Flame Ionization"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["analysis"],"descriptor":"Parasympatholytics"},{"qualifiers":["analysis"],"descriptor":"Piperidines"},{"qualifiers":["analysis"],"descriptor":"Procyclidine"},{"qualifiers":["analysis"],"descriptor":"Pyrrolidines"},{"qualifiers":["analysis","pharmacokinetics"],"descriptor":"Trihexyphenidyl"}],"pmid":"2573609","title":"Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids."},{"mesh_descriptors":[{"qualifiers":["chemical synthesis"],"descriptor":"Antiparkinson Agents"},{"qualifiers":["chemical synthesis"],"descriptor":"Bridged Bicyclo Compounds"},{"qualifiers":["chemical synthesis"],"descriptor":"Bridged-Ring Compounds"},{"qualifiers":[],"descriptor":"Chemical Phenomena"},{"qualifiers":[],"descriptor":"Chemistry"},{"qualifiers":["chemical synthesis"],"descriptor":"Piperazines"}],"pmid":"862878","title":"[Bicyclic analogs of piperazine. XII. (1) - Synthesis of 3,8-diazabicyclo/3,2,1/octanes as potential antiparkinson agents]."},{"mesh_descriptors":[{"qualifiers":["pharmacology"],"descriptor":"Acetylcholine"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["pharmacology"],"descriptor":"Antiparkinson Agents"},{"qualifiers":[],"descriptor":"Denervation"},{"qualifiers":["drug effects","physiology"],"descriptor":"Diaphragm"},{"qualifiers":[],"descriptor":"Electric Stimulation"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["pharmacology"],"descriptor":"Hemicholinium 3"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["drug effects"],"descriptor":"Muscle Contraction"},{"qualifiers":["pharmacology"],"descriptor":"Neostigmine"},{"qualifiers":["drug effects","physiology"],"descriptor":"Phrenic Nerve"},{"qualifiers":["pharmacology"],"descriptor":"Piperidines"},{"qualifiers":[],"descriptor":"Rats"},{"qualifiers":["pharmacology"],"descriptor":"Tubocurarine"}],"pmid":"1267542","title":"Cycrimine on rat diaphragm."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Biomedical Research"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapy"],"descriptor":"Motion Sickness"},{"qualifiers":[],"descriptor":"Muscarinic Antagonists"},{"qualifiers":[],"descriptor":"Piperidines"},{"qualifiers":[],"descriptor":"Procyclidine"},{"qualifiers":["analogs &amp; derivatives"],"descriptor":"Trihexyphenidyl"}],"pmid":"13575361","title":"Effectiveness of procyclidine hydrochloride (kemadrin) and cycrimine hydrochloride (pagitane) in the prevention of airsickness."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Nervous System Diseases"},{"qualifiers":["therapy"],"descriptor":"Parkinson Disease"},{"qualifiers":[],"descriptor":"Piperidines"},{"qualifiers":["analogs &amp; derivatives"],"descriptor":"Trihexyphenidyl"}],"pmid":"13477721","title":"[Cycrimine, a new drug in the treatment of Parkinson's disease &amp; Parkinsonism]."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Cardiovascular Agents"},{"qualifiers":["therapeutic use"],"descriptor":"Muscle Relaxants, Central"},{"qualifiers":["therapy"],"descriptor":"Parkinson Disease"},{"qualifiers":[],"descriptor":"Parkinsonian Disorders"},{"qualifiers":[],"descriptor":"Piperidines"}],"pmid":"14371520","title":"[Symptomatic therapeutic effect of cycrimine HCl in parkinsonian syndromes]."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Cardiovascular Agents"},{"qualifiers":[],"descriptor":"Muscarinic Antagonists"},{"qualifiers":[],"descriptor":"Muscle Relaxants, Central"},{"qualifiers":["therapy"],"descriptor":"Parkinson Disease"},{"qualifiers":[],"descriptor":"Piperidines"}],"pmid":"13221464","title":"NEW AND nonofficial remedies: cycrimine hydrochloride."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":3,"matched_diseases":["Parkinson Disease","Parkinsonian Disorders","Nervous System Diseases"],"diseases_with_associations":3,"total_mesh_terms":95,"total_publications_analyzed":10},"disease_associations":{"Parkinson Disease":[{"pmid":"13477721","title":"[Cycrimine, a new drug in the treatment of Parkinson's disease &amp; Parkinsonism].","qualifiers":["therapy"]},{"pmid":"14371520","title":"[Symptomatic therapeutic effect of cycrimine HCl in parkinsonian syndromes].","qualifiers":["therapy"]},{"pmid":"13221464","title":"NEW AND nonofficial remedies: cycrimine hydrochloride.","qualifiers":["therapy"]}],"Parkinsonian Disorders":[{"pmid":"14371520","title":"[Symptomatic therapeutic effect of cycrimine HCl in parkinsonian syndromes].","qualifiers":[]}],"Nervous System Diseases":[{"pmid":"13477721","title":"[Cycrimine, a new drug in the treatment of Parkinson's disease &amp; Parkinsonism].","qualifiers":[]}]}},"pmids":["32108589","8938597","8649435","2573609","862878","1267542","13575361","13477721","14371520","13221464"]},{"indication":"For the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions","drug_name":"Flumethasone","pmids_analyzed":["40484303","39983925","38968458","37835233","37351165","37105482","34224277","32751592","35117743","31954771"],"count":383,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"China"},{"qualifiers":["analysis"],"descriptor":"Glucocorticoids"},{"qualifiers":["analysis"],"descriptor":"Soil Pollutants"},{"qualifiers":[],"descriptor":"Environmental Monitoring"},{"qualifiers":["chemistry"],"descriptor":"Soil"},{"qualifiers":[],"descriptor":"Risk Assessment"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["analysis"],"descriptor":"Endocrine Disruptors"},{"qualifiers":[],"descriptor":"Humans"}],"pmid":"40484303","title":"Occurrence, distribution, and potential risk of 61 glucocorticoids in soils in Shandong Province, China."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["drug effects","metabolism"],"descriptor":"Pancreatic Stellate Cells"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy","pathology","metabolism"],"descriptor":"Pancreatic Neoplasms"},{"qualifiers":["drug effects"],"descriptor":"Tumor Microenvironment"},{"qualifiers":["drug therapy","pathology"],"descriptor":"Carcinoma, Pancreatic Ductal"},{"qualifiers":[],"descriptor":"Cell Line, Tumor"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":["chemistry","administration &amp; dosage"],"descriptor":"Albumins"},{"qualifiers":[],"descriptor":"Mice, Inbred C57BL"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Antineoplastic Agents"}],"pmid":"39983925","title":"Albumin-conjugated flumethasone for targeting and normalization of pancreatic stellate cells."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use"],"descriptor":"Purines"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["therapeutic use"],"descriptor":"Pyrazoles"},{"qualifiers":["therapeutic use"],"descriptor":"Sulfonamides"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":["therapeutic use"],"descriptor":"Azetidines"},{"qualifiers":["therapeutic use"],"descriptor":"Janus Kinase Inhibitors"},{"qualifiers":["drug therapy"],"descriptor":"Epidermolysis Bullosa Dystrophica"},{"qualifiers":[],"descriptor":"Administration, Oral"}],"pmid":"38968458","title":"Epidermolysis Bullosa Pruriginosa treated with baricitinib: A case report."},{"mesh_descriptors":[],"pmid":"37835233","title":"Effect of Thermal Inactivation on Antioxidant, Anti-Inflammatory Activities and Chemical Profile of Postbiotics."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy","genetics"],"descriptor":"Pancreatic Neoplasms"},{"qualifiers":[],"descriptor":"Gemcitabine"},{"qualifiers":["therapeutic use"],"descriptor":"Antineoplastic Combined Chemotherapy Protocols"},{"qualifiers":[],"descriptor":"Cohort Studies"}],"pmid":"37351165","title":"Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multicenter cohort study based on super-enhancer profiling."},{"mesh_descriptors":[{"qualifiers":["chemistry"],"descriptor":"Rivers"},{"qualifiers":["analysis"],"descriptor":"Water Pollutants, Chemical"},{"qualifiers":["analysis"],"descriptor":"Particulate Matter"},{"qualifiers":[],"descriptor":"Adrenal Cortex Hormones"},{"qualifiers":[],"descriptor":"Water"},{"qualifiers":[],"descriptor":"China"},{"qualifiers":[],"descriptor":"Dust"},{"qualifiers":[],"descriptor":"Environmental Monitoring"},{"qualifiers":["chemistry"],"descriptor":"Geologic Sediments"}],"pmid":"37105482","title":"Suspended particulate matter-associated environmental corticosteroids in the Pearl River, China: Occurrence, distribution, and partitioning."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Clioquinol"},{"qualifiers":["analogs &amp; derivatives"],"descriptor":"Flumethasone"},{"qualifiers":[],"descriptor":"Spectrophotometry"}],"pmid":"34224277","title":"Comparative study of novel green UV-spectrophotometric platforms for simultaneous rapid analysis of flumethasone pivalate and clioquinol in their combined formulation."},{"mesh_descriptors":[{"qualifiers":["chemistry"],"descriptor":"Capecitabine"},{"qualifiers":["chemistry"],"descriptor":"Diosgenin"},{"qualifiers":["chemistry"],"descriptor":"Genistein"},{"qualifiers":["methods"],"descriptor":"Nanotechnology"},{"qualifiers":["chemistry"],"descriptor":"Phytochemicals"},{"qualifiers":["chemistry"],"descriptor":"Spirostans"},{"qualifiers":["chemical synthesis","chemistry"],"descriptor":"Sulfhydryl Compounds"}],"pmid":"32751592","title":"Synthesis of Thiol Derivatives of Biological Active Compounds for Nanotechnology Application."},{"mesh_descriptors":[],"pmid":"35117743","title":"Atezolizumab-induced psoriasis in a patient with metastatic lung cancer-a case report."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["pharmacology"],"descriptor":"Anti-Inflammatory Agents"},{"qualifiers":["pharmacology"],"descriptor":"Antineoplastic Agents"},{"qualifiers":[],"descriptor":"Apoptosis"},{"qualifiers":["genetics","metabolism"],"descriptor":"Biomarkers, Tumor"},{"qualifiers":[],"descriptor":"Cell Proliferation"},{"qualifiers":[],"descriptor":"Drug Resistance, Neoplasm"},{"qualifiers":[],"descriptor":"Drug Synergism"},{"qualifiers":[],"descriptor":"Drug Therapy, Combination"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["pharmacology"],"descriptor":"Flumethasone"},{"qualifiers":[],"descriptor":"Gene Expression Regulation, Neoplastic"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy","metabolism","pathology"],"descriptor":"Lung Neoplasms"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":[],"descriptor":"Mice, Inbred BALB C"},{"qualifiers":[],"descriptor":"Mice, Nude"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"NF-E2-Related Factor 2"},{"qualifiers":[],"descriptor":"Prognosis"},{"qualifiers":[],"descriptor":"Tumor Cells, Cultured"},{"qualifiers":[],"descriptor":"Xenograft Model Antitumor Assays"}],"pmid":"31954771","title":"Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":1,"matched_diseases":["Epidermolysis Bullosa Dystrophica"],"diseases_with_associations":1,"total_mesh_terms":77,"total_publications_analyzed":10},"disease_associations":{"Epidermolysis Bullosa Dystrophica":[{"pmid":"38968458","title":"Epidermolysis Bullosa Pruriginosa treated with baricitinib: A case report.","qualifiers":["drug therapy"]}]}},"pmids":["40484303","39983925","38968458","37835233","37351165","37105482","34224277","32751592","35117743","31954771","31840435","30954817","30828791","30702391","30478515","30080272","30015958","29580053","29559602","28994213","28556446","26797492","26600419","26004577","25569131","25448970","24880571","23200376","22819726","22548394","21905839","21729449","21324709","21242108","21140678","21112257","20457014","20071003","19485221","19423120","19286019","19073240","18506427","18486661","18322906","17903127","17386789","22063222","17055710","17010347"]},{"indication":"Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.[L43150,L44216,L45778]","drug_name":"Deucravacitinib","pmids_analyzed":["40571687","40568688","40568686","40562168","40557729","40519492","40490621","40476606","40475785","40468645"],"count":256,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["physiopathology","complications","epidemiology","drug therapy","therapy"],"descriptor":"Psoriasis"},{"qualifiers":[],"descriptor":"Arthritis, Psoriatic"}],"pmid":"40571687","title":"Psoriasis."},{"mesh_descriptors":[],"pmid":"40568688","title":"Male and female pattern hair loss."},{"mesh_descriptors":[],"pmid":"40568686","title":"Psoriasis: an update on topical and systemic therapies."},{"mesh_descriptors":[],"pmid":"40562168","title":"[[Translated article]]RF - New Treatments in Cutaneous Lupus Erythematosus: Current and Future Perspectives."},{"mesh_descriptors":[],"pmid":"40557729","title":"Deucravacitinib: Long-term safety and efficacy reaffirm its place in the psoriasis treatment landscape."},{"mesh_descriptors":[],"pmid":"40519492","title":"Deucravacitinib Treatment for Psoriasis Complicated by Myelodysplastic Syndrome Without Exacerbation of the Underlying Hematologic Disorder: A Case Report."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["drug therapy","complications","diagnosis"],"descriptor":"Psoriasis"},{"qualifiers":["drug therapy","complications","diagnosis"],"descriptor":"Chronic Urticaria"},{"qualifiers":["therapeutic use"],"descriptor":"Protein Kinase Inhibitors"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":[],"descriptor":"Adult"}],"pmid":"40490621","title":"Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria."},{"mesh_descriptors":[],"pmid":"40476606","title":"Successful Management of Multidrug-Resistant Psoriatic Arthritis Coexisting With Rheumatoid Arthritis Using a TYK2 Inhibitor Deucravacitinib-Based Regimen."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["drug therapy","complications","diagnosis"],"descriptor":"Psoriasis"},{"qualifiers":["drug therapy","complications","diagnosis"],"descriptor":"Osteomyelitis"},{"qualifiers":[],"descriptor":"Young Adult"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":["antagonists &amp; inhibitors"],"descriptor":"TYK2 Kinase"},{"qualifiers":["therapeutic use"],"descriptor":"Protein Kinase Inhibitors"}],"pmid":"40475785","title":"Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["economics","therapeutic use"],"descriptor":"Anti-Inflammatory Agents, Non-Steroidal"},{"qualifiers":[],"descriptor":"Cost-Benefit Analysis"},{"qualifiers":[],"descriptor":"Cost-Effectiveness Analysis"},{"qualifiers":[],"descriptor":"Japan"},{"qualifiers":[],"descriptor":"Markov Chains"},{"qualifiers":["drug therapy"],"descriptor":"Psoriasis"},{"qualifiers":[],"descriptor":"Quality of Life"},{"qualifiers":[],"descriptor":"Quality-Adjusted Life Years"},{"qualifiers":["economics","therapeutic use"],"descriptor":"Quinazolinones"},{"qualifiers":[],"descriptor":"Severity of Illness Index"},{"qualifiers":["analogs &amp; derivatives","economics","therapeutic use","analogs &amp; derivatives"],"descriptor":"Thalidomide"},{"qualifiers":[],"descriptor":"Randomized Controlled Trials as Topic"},{"qualifiers":[],"descriptor":"Clinical Trials, Phase III as Topic"},{"qualifiers":[],"descriptor":"Multicenter Studies as Topic"}],"pmid":"40468645","title":"A cost-effectiveness analysis of deucravacitinib <i>vs.</i> apremilast in&#xa0;moderate-to-severe psoriasis patients in Japan."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":4,"matched_diseases":["Arthritis, Psoriatic","Chronic Urticaria","Osteomyelitis","Psoriasis"],"diseases_with_associations":4,"total_mesh_terms":37,"total_publications_analyzed":10},"disease_associations":{"Arthritis, Psoriatic":[{"pmid":"40571687","title":"Psoriasis.","qualifiers":[]}],"Chronic Urticaria":[{"pmid":"40490621","title":"Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria.","qualifiers":["drug therapy","complications","diagnosis"]}],"Osteomyelitis":[{"pmid":"40475785","title":"Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis.","qualifiers":["drug therapy","complications","diagnosis"]}],"Psoriasis":[{"pmid":"40571687","title":"Psoriasis.","qualifiers":["physiopathology","complications","epidemiology","drug therapy","therapy"]},{"pmid":"40490621","title":"Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria.","qualifiers":["drug therapy","complications","diagnosis"]},{"pmid":"40475785","title":"Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis.","qualifiers":["drug therapy","complications","diagnosis"]},{"pmid":"40468645","title":"A cost-effectiveness analysis of deucravacitinib <i>vs.</i> apremilast in&#xa0;moderate-to-severe psoriasis patients in Japan.","qualifiers":["drug therapy"]}]}},"pmids":["40571687","40568688","40568686","40562168","40557729","40519492","40490621","40476606","40475785","40468645","40452604","40451616","40445270","40439875","40411449","40378946","40372702","40355364","40353105","40351849","40320905","40314052","40304108","40276972","40268819","40252783","40237138","40204473","40204141","40202574","40200906","40177824","40176687","40113724","40109802","40095888","40095854","40078858","40066907","40048065","40047795","40045918","40029105","39918727","39916637","39913225","39891469","39879362","39873274","39838595"]},{"indication":"The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies.[L1064] It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.","drug_name":"Ubidecarenone","pmids_analyzed":["40225540","38457558","37095452","36645365","35952450","34314511","33866314","33707480","32807842","32743982"],"count":75,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[],"pmid":"40225540","title":"Leber Hereditary Optic Neuropathy With Magnetic Resonance Imaging Findings Suggestive of Optic Perineuritis and Optic Neuritis: A Diagnostic Challenge."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Young Adult"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Global Longitudinal Strain"},{"qualifiers":[],"descriptor":"Acetylcarnitine"},{"qualifiers":[],"descriptor":"Point Mutation"},{"qualifiers":["genetics"],"descriptor":"Deafness"},{"qualifiers":["complications","genetics"],"descriptor":"Diabetes Mellitus, Type 2"},{"qualifiers":["complications"],"descriptor":"Hearing Loss, Sensorineural"},{"qualifiers":["complications"],"descriptor":"Hearing Loss"},{"qualifiers":["complications"],"descriptor":"Cardiomyopathies"},{"qualifiers":[],"descriptor":"Disease Progression"},{"qualifiers":["genetics"],"descriptor":"DNA, Mitochondrial"},{"qualifiers":[],"descriptor":"Mitochondrial Diseases"}],"pmid":"38457558","title":"Chronological change of left ventricular global longitudinal strain in patients with maternally inherited diabetes and deafness: A case series."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["genetics"],"descriptor":"MELAS Syndrome"},{"qualifiers":["complications"],"descriptor":"Optic Neuropathy, Ischemic"},{"qualifiers":[],"descriptor":"Acidosis, Lactic"},{"qualifiers":[],"descriptor":"Mutation"},{"qualifiers":["complications"],"descriptor":"Stroke"},{"qualifiers":["complications"],"descriptor":"Optic Nerve Diseases"},{"qualifiers":["genetics"],"descriptor":"Optic Atrophy, Hereditary, Leber"},{"qualifiers":["genetics"],"descriptor":"DNA, Mitochondrial"},{"qualifiers":["complications"],"descriptor":"Vision Disorders"},{"qualifiers":["complications"],"descriptor":"Headache"}],"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Trace Elements"},{"qualifiers":[],"descriptor":"Alopecia Areata"},{"qualifiers":[],"descriptor":"Hair"},{"qualifiers":[],"descriptor":"Cosmetics"},{"qualifiers":[],"descriptor":"Dietary Supplements"}],"pmid":"36645365","title":"Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic treatment."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Creatinine"},{"qualifiers":[],"descriptor":"Dental Amalgam"},{"qualifiers":[],"descriptor":"Glutathione"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["toxicity"],"descriptor":"Mercuric Chloride"},{"qualifiers":[],"descriptor":"Mercury"},{"qualifiers":["genetics","metabolism"],"descriptor":"PTEN Phosphohydrolase"},{"qualifiers":["metabolism"],"descriptor":"Phosphatidylinositol 3-Kinases"},{"qualifiers":["metabolism"],"descriptor":"Proto-Oncogene Proteins c-akt"},{"qualifiers":["metabolism"],"descriptor":"RNA, Messenger"},{"qualifiers":[],"descriptor":"Rats"},{"qualifiers":[],"descriptor":"STAT5 Transcription Factor"},{"qualifiers":[],"descriptor":"Signal Transduction"},{"qualifiers":[],"descriptor":"Sulfhydryl Compounds"},{"qualifiers":["metabolism"],"descriptor":"Tensins"},{"qualifiers":["analogs &amp; derivatives"],"descriptor":"Ubiquinone"},{"qualifiers":[],"descriptor":"Urea"}],"pmid":"35952450","title":"Ubiquitous toxicity of Mercuric Chloride in target tissues and organs: Impact of Ubidecarenone and liposomal-Ubidecarenone STAT 5A/ PTEN /PI3K/AKT signaling pathways."},{"mesh_descriptors":[{"qualifiers":["diagnosis","prevention &amp; control"],"descriptor":"COVID-19"},{"qualifiers":[],"descriptor":"Cohort Studies"},{"qualifiers":["methods"],"descriptor":"Drug Repositioning"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["administration &amp; dosage"],"descriptor":"Pneumococcal Vaccines"},{"qualifiers":["methods"],"descriptor":"Product Surveillance, Postmarketing"},{"qualifiers":[],"descriptor":"Retrospective Studies"},{"qualifiers":[],"descriptor":"COVID-19 Drug Treatment"}],"pmid":"34314511","title":"DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Age Factors"},{"qualifiers":[],"descriptor":"Diabetes Mellitus"},{"qualifiers":[],"descriptor":"Dietary Supplements"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Oxidative Stress"},{"qualifiers":["analogs &amp; derivatives"],"descriptor":"Ubiquinone"}],"pmid":"33866314","title":"Diabetes, Age, and Duration of Supplementation Subgroup Analysis for the Effect of Coenzyme Q10 on Oxidative Stress: A Systematic Review and Meta-Analysis."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Apoptosis"},{"qualifiers":[],"descriptor":"Cell Line, Tumor"},{"qualifiers":[],"descriptor":"Cell Proliferation"},{"qualifiers":[],"descriptor":"Cell Respiration"},{"qualifiers":[],"descriptor":"Cell Survival"},{"qualifiers":["metabolism"],"descriptor":"Electron Transport Complex II"},{"qualifiers":[],"descriptor":"Glycerol-3-Phosphate Dehydrogenase (NAD+)"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Membrane Potential, Mitochondrial"},{"qualifiers":[],"descriptor":"Mice, Nude"},{"qualifiers":["metabolism"],"descriptor":"Mitochondria"},{"qualifiers":["pathology"],"descriptor":"Organoids"},{"qualifiers":[],"descriptor":"Oxidative Stress"},{"qualifiers":[],"descriptor":"Oxygen Consumption"},{"qualifiers":["metabolism","pathology"],"descriptor":"Pancreatic Neoplasms"},{"qualifiers":["metabolism"],"descriptor":"Reactive Oxygen Species"},{"qualifiers":[],"descriptor":"Substrate Specificity"},{"qualifiers":["analogs &amp; derivatives","metabolism"],"descriptor":"Ubiquinone"},{"qualifiers":[],"descriptor":"Mice"}],"pmid":"33707480","title":"Elevated levels of mitochondrial CoQ<sub>10</sub> induce ROS-mediated apoptosis in pancreatic cancer."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":["drug effects"],"descriptor":"Cell Cycle Checkpoints"},{"qualifiers":[],"descriptor":"Cell Line, Tumor"},{"qualifiers":["drug effects"],"descriptor":"Cell Proliferation"},{"qualifiers":[],"descriptor":"Drug Delivery Systems"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["drug therapy","pathology"],"descriptor":"Glioma"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["chemistry"],"descriptor":"Lipids"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":[],"descriptor":"NIH 3T3 Cells"},{"qualifiers":["chemistry"],"descriptor":"Nanoparticles"},{"qualifiers":[],"descriptor":"Oxidation-Reduction"},{"qualifiers":["chemistry"],"descriptor":"Pharmaceutical Preparations"},{"qualifiers":[],"descriptor":"Rats, Wistar"},{"qualifiers":["metabolism"],"descriptor":"Superoxides"},{"qualifiers":["administration &amp; dosage","analogs &amp; derivatives","pharmacology","therapeutic use"],"descriptor":"Ubiquinone"}],"pmid":"32807842","title":"High levels of ubidecarenone (oxidized CoQ<sub>10</sub>) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":["genetics","pathology"],"descriptor":"Cerebellar Ataxia"},{"qualifiers":["diagnostic imaging","pathology"],"descriptor":"Cerebellum"},{"qualifiers":[],"descriptor":"Gait"},{"qualifiers":[],"descriptor":"Heterozygote"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["deficiency","genetics"],"descriptor":"Mitochondrial Proteins"},{"qualifiers":[],"descriptor":"Mutation"},{"qualifiers":["genetics","pathology"],"descriptor":"Scoliosis"},{"qualifiers":["genetics","pathology"],"descriptor":"Tremor"}],"pmid":"32743982","title":"Primary coenzyme Q10 deficiency due to COQ8A gene mutations."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":15,"matched_diseases":["Optic Neuropathy, Ischemic","COVID-19","Vision Disorders","Diabetes Mellitus","Hearing Loss, Sensorineural","Mitochondrial Diseases","Deafness","Optic Atrophy, Hereditary, Leber","Cardiomyopathies","Stroke","Optic Nerve Diseases","Alopecia Areata","MELAS Syndrome","Acidosis, Lactic","Diabetes Mellitus, Type 2"],"diseases_with_associations":15,"total_mesh_terms":116,"total_publications_analyzed":10},"disease_associations":{"Optic Neuropathy, Ischemic":[{"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation.","qualifiers":["complications"]}],"COVID-19":[{"pmid":"34314511","title":"DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing.","qualifiers":["diagnosis","prevention &amp; control"]}],"Vision Disorders":[{"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation.","qualifiers":["complications"]}],"Diabetes Mellitus":[{"pmid":"33866314","title":"Diabetes, Age, and Duration of Supplementation Subgroup Analysis for the Effect of Coenzyme Q10 on Oxidative Stress: A Systematic Review and Meta-Analysis.","qualifiers":[]}],"Hearing Loss, Sensorineural":[{"pmid":"38457558","title":"Chronological change of left ventricular global longitudinal strain in patients with maternally inherited diabetes and deafness: A case series.","qualifiers":["complications"]}],"Mitochondrial Diseases":[{"pmid":"38457558","title":"Chronological change of left ventricular global longitudinal strain in patients with maternally inherited diabetes and deafness: A case series.","qualifiers":[]}],"Deafness":[{"pmid":"38457558","title":"Chronological change of left ventricular global longitudinal strain in patients with maternally inherited diabetes and deafness: A case series.","qualifiers":["genetics"]}],"Optic Atrophy, Hereditary, Leber":[{"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation.","qualifiers":["genetics"]}],"Cardiomyopathies":[{"pmid":"38457558","title":"Chronological change of left ventricular global longitudinal strain in patients with maternally inherited diabetes and deafness: A case series.","qualifiers":["complications"]}],"Stroke":[{"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation.","qualifiers":["complications"]}],"Optic Nerve Diseases":[{"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation.","qualifiers":["complications"]}],"Alopecia Areata":[{"pmid":"36645365","title":"Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic treatment.","qualifiers":[]}],"MELAS Syndrome":[{"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation.","qualifiers":["genetics"]}],"Acidosis, Lactic":[{"pmid":"37095452","title":"Ischemic optic neuropathy as first presentation in patient with m.3243&#xa0;A&#x2009;&gt;&#x2009;G MELAS classic mutation.","qualifiers":[]}],"Diabetes Mellitus, Type 2":[{"pmid":"38457558","title":"Chronological change of left ventricular global longitudinal strain in patients with maternally inherited diabetes and deafness: A case series.","qualifiers":["complications","genetics"]}]}},"pmids":["40225540","38457558","37095452","36645365","35952450","34314511","33866314","33707480","32807842","32743982","29941831","28552692","28450207","28315731","27940755","26292508","25977402","25544601","24164873","24072051","23621001","19652461","19365779","19281730","19049318","18727527","17955966","16872244","16497495","16395203","16198039","16142989","16048353","15743112","15707737","15350679","14681312","12557713","11460879","11442266","11400555","11193494","10972372","10822909","10638164","9868308","9621803","8734141","7564816","7715371"]},{"indication":"Sulconazole solution 1.0% is indicated for the treatment of tinea cruris and tinea corporis caused by _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_, and _Microsporum canis_; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athletes foot).[L44592,L44597]","drug_name":"Sulconazole","pmids_analyzed":["39671810","30000485","38395517","38250065","38005230","37076047","36657529","36534331","35847500","34516894"],"count":103,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":["drug effects","pathogenicity","metabolism"],"descriptor":"Klebsiella pneumoniae"},{"qualifiers":["pharmacology"],"descriptor":"Glucose"},{"qualifiers":[],"descriptor":"Microbial Sensitivity Tests"},{"qualifiers":["pharmacology"],"descriptor":"Anti-Bacterial Agents"},{"qualifiers":["pharmacology"],"descriptor":"Trehalose"},{"qualifiers":["metabolism"],"descriptor":"Reactive Oxygen Species"},{"qualifiers":["pharmacology"],"descriptor":"Carbapenems"},{"qualifiers":["microbiology","drug therapy"],"descriptor":"Klebsiella Infections"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["metabolism"],"descriptor":"Adenosine Triphosphate"},{"qualifiers":["metabolism"],"descriptor":"NAD"},{"qualifiers":["drug effects"],"descriptor":"Drug Resistance, Multiple, Bacterial"},{"qualifiers":["drug effects"],"descriptor":"Biofilms"},{"qualifiers":["drug effects"],"descriptor":"Carbapenem-Resistant Enterobacteriaceae"}],"pmid":"39671810","title":"Antimicrobial effect of sulconazole in combination with glucose/trehalose against carbapenem-resistant hypervirulent Klebsiella pneumoniae persisters."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Pyroptosis"},{"qualifiers":["metabolism"],"descriptor":"Interferon-gamma"},{"qualifiers":["metabolism"],"descriptor":"Monocytes"},{"qualifiers":["pharmacology"],"descriptor":"Lipopolysaccharides"},{"qualifiers":["metabolism"],"descriptor":"Macrophages"},{"qualifiers":["pharmacology","metabolism"],"descriptor":"Imidazoles"},{"qualifiers":["metabolism"],"descriptor":"Cytokines"}],"pmid":"38395517","title":"Sulconazole induces pyroptosis promoted by interferon-&#x3b3; in monocyte/macrophage lineage cells."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"NF-kappa B"},{"qualifiers":[],"descriptor":"Calcium"},{"qualifiers":[],"descriptor":"Programmed Cell Death 1 Receptor"},{"qualifiers":[],"descriptor":"Zebrafish"},{"qualifiers":[],"descriptor":"Calcium Signaling"},{"qualifiers":["drug therapy"],"descriptor":"Neoplasms"},{"qualifiers":[],"descriptor":"Imidazoles"}],"pmid":"38250065","title":"Sulconazole inhibits PD-1 expression in immune cells and cancer cells malignant phenotype through NF-&#x3ba;B and calcium activity repression."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Rabbits"},{"qualifiers":["chemistry"],"descriptor":"Antifungal Agents"},{"qualifiers":[],"descriptor":"Delayed-Action Preparations"},{"qualifiers":["chemistry"],"descriptor":"Nanoparticles"},{"qualifiers":[],"descriptor":"Mycoses"},{"qualifiers":[],"descriptor":"Particle Size"},{"qualifiers":["chemistry"],"descriptor":"Drug Carriers"}],"pmid":"38005230","title":"Sulconazole-Loaded Solid Lipid Nanoparticles for Enhanced Antifungal Activity: In Vitro and In Vivo Approach."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Proteomics"},{"qualifiers":[],"descriptor":"Cell Line, Tumor"},{"qualifiers":["metabolism"],"descriptor":"Esophageal Neoplasms"},{"qualifiers":[],"descriptor":"Radiation Tolerance"},{"qualifiers":[],"descriptor":"Oxidative Stress"},{"qualifiers":[],"descriptor":"Apoptosis"},{"qualifiers":[],"descriptor":"Glycolysis"}],"pmid":"37076047","title":"Sulconazole Induces PANoptosis by Triggering Oxidative Stress and Inhibiting Glycolysis to Increase Radiosensitivity in Esophageal Cancer."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Swine"},{"qualifiers":[],"descriptor":"Constriction, Pathologic"},{"qualifiers":[],"descriptor":"Delayed-Action Preparations"},{"qualifiers":[],"descriptor":"Collagen"},{"qualifiers":["pathology"],"descriptor":"Extracellular Matrix"},{"qualifiers":[],"descriptor":"Fibrosis"}],"pmid":"36657529","title":"Injectable, Drug-Eluting Nanocrystals Prevent Fibrosis and Stricture Formation In&#xa0;Vivo."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Animals"},{"qualifiers":[],"descriptor":"Mice"},{"qualifiers":[],"descriptor":"Fluorescent Dyes"},{"qualifiers":["metabolism","pharmacology"],"descriptor":"Sodium"},{"qualifiers":[],"descriptor":"HEK293 Cells"},{"qualifiers":[],"descriptor":"Mice, Nude"},{"qualifiers":["metabolism"],"descriptor":"Phosphatidylinositol 3-Kinases"},{"qualifiers":[],"descriptor":"Symporters"},{"qualifiers":["metabolism"],"descriptor":"Biotin"},{"qualifiers":[],"descriptor":"Signal Transduction"},{"qualifiers":["diagnostic imaging","drug therapy"],"descriptor":"Fibrosarcoma"}],"pmid":"36534331","title":"Sodium Multivitamin Transporter-Targeted Fluorochrome Facilitates Enhanced Metabolic Evaluation of Tumors Through Coenzyme-R Dependent Intracellular Signaling Pathways."},{"mesh_descriptors":[],"pmid":"35847500","title":"A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes."},{"mesh_descriptors":[],"pmid":"34516894","title":"A chemical biology approach reveals a dependency of glioblastoma on biotin distribution."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":2,"matched_diseases":["Klebsiella Infections","Mycoses"],"diseases_with_associations":2,"total_mesh_terms":68,"total_publications_analyzed":9},"disease_associations":{"Klebsiella Infections":[{"pmid":"39671810","title":"Antimicrobial effect of sulconazole in combination with glucose/trehalose against carbapenem-resistant hypervirulent Klebsiella pneumoniae persisters.","qualifiers":["microbiology","drug therapy"]}],"Mycoses":[{"pmid":"38005230","title":"Sulconazole-Loaded Solid Lipid Nanoparticles for Enhanced Antifungal Activity: In Vitro and In Vivo Approach.","qualifiers":[]}]}},"pmids":["39671810","30000485","38395517","38250065","38005230","37076047","36657529","36534331","35847500","34516894","33361643","32928373","32636702","32376018","31480284","31451730","31353071","31239665","31121099","31035691","30439668","30010340","29736295","28811501","28260509","27761807","25421375","25130087","24604679","24363112","23869955","21341170","20926087","20828966","19496569","19135678","21696646","19099359","17607804","17357619","17275012","16807364","16620478","16510062","16441623","16078699","15544342","15499919","15062918","14970634"]},{"indication":"Iophendylate is used as a contrast agent to locate spinal tumors.","drug_name":"Iophendylate","pmids_analyzed":["38547442","36544579","30922531","30823879","29323010","28639826","27908202","27726152","23578988","22610440"],"count":320,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Iophendylate"},{"qualifiers":[],"descriptor":"Myelography"},{"qualifiers":[],"descriptor":"Contrast Media"},{"qualifiers":["diagnostic imaging"],"descriptor":"Brain"},{"qualifiers":[],"descriptor":"Head"}],"pmid":"38547442","title":"Migration of Iophendylate Myelography Contrast to the Brain With Successful Thrombectomy."},{"mesh_descriptors":[],"pmid":"36544579","title":"Cranial Polyneuropathy Secondary to Remote Iophendylate Myelography."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":["pathology","surgery"],"descriptor":"Dura Mater"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Lumbar Vertebrae"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["pathology","surgery"],"descriptor":"Osteosarcoma"},{"qualifiers":["pathology","surgery"],"descriptor":"Spinal Neoplasms"}],"pmid":"30922531","title":"Intradural osteogenic sarcoma in the lumbar spine."},{"mesh_descriptors":[],"pmid":"30823879","title":"Correction to: Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["metabolism"],"descriptor":"Iophendylate"},{"qualifiers":["diagnostic imaging","metabolism"],"descriptor":"Lymphoma, Non-Hodgkin"},{"qualifiers":[],"descriptor":"Magnetic Resonance Imaging"},{"qualifiers":["diagnostic imaging"],"descriptor":"Spinal Cord"},{"qualifiers":["diagnostic imaging","pathology"],"descriptor":"Subarachnoid Space"},{"qualifiers":[],"descriptor":"Tomography Scanners, X-Ray Computed"}],"pmid":"29323010","title":"Revisiting a historical phenomenon: Myodil droplets in the subarachnoid space."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["diagnostic imaging","etiology"],"descriptor":"Arachnoiditis"},{"qualifiers":[],"descriptor":"Chronic Disease"},{"qualifiers":[],"descriptor":"Contrast Media"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Magnetic Resonance Imaging"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Retrospective Studies"},{"qualifiers":[],"descriptor":"Tomography, X-Ray Computed"}],"pmid":"28639826","title":"Imaging Appearance of Advanced Chronic Adhesive Arachnoiditis: A Retrospective Review."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged, 80 and over"},{"qualifiers":["adverse effects"],"descriptor":"Contrast Media"},{"qualifiers":["diagnostic imaging"],"descriptor":"Extravasation of Diagnostic and Therapeutic Materials"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects"],"descriptor":"Iophendylate"},{"qualifiers":["adverse effects"],"descriptor":"Myelography"},{"qualifiers":["diagnostic imaging"],"descriptor":"Subarachnoid Space"},{"qualifiers":[],"descriptor":"Tomography, X-Ray Computed"}],"pmid":"27908202","title":"Intracranial migration of iophendylate four decades after conventional myelography."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":["diagnostic imaging","metabolism"],"descriptor":"Cerebellopontine Angle"},{"qualifiers":["adverse effects","metabolism"],"descriptor":"Contrast Media"},{"qualifiers":[],"descriptor":"Diagnosis, Differential"},{"qualifiers":["diagnostic imaging","metabolism"],"descriptor":"Ear, Inner"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects","metabolism"],"descriptor":"Iophendylate"},{"qualifiers":[],"descriptor":"Magnetic Resonance Imaging"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":["diagnostic imaging"],"descriptor":"Neuroma, Acoustic"},{"qualifiers":[],"descriptor":"Time Factors"},{"qualifiers":[],"descriptor":"Tomography, X-Ray Computed"}],"pmid":"27726152","title":"Pantopaque contrast mimicking intracanalicular vestibular schwannoma."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Aged"},{"qualifiers":[],"descriptor":"Fatal Outcome"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":[],"descriptor":"Laminectomy"},{"qualifiers":["pathology","surgery"],"descriptor":"Lumbar Vertebrae"},{"qualifiers":["pathology","surgery"],"descriptor":"Osteosarcoma"},{"qualifiers":["pathology","surgery"],"descriptor":"Spinal Neoplasms"}],"pmid":"23578988","title":"A case of intradural osteosarcoma of the spine."},{"mesh_descriptors":[{"qualifiers":["adverse effects"],"descriptor":"Contrast Media"},{"qualifiers":["diagnosis","etiology"],"descriptor":"Cysts"},{"qualifiers":[],"descriptor":"Diagnosis, Differential"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["adverse effects"],"descriptor":"Iophendylate"},{"qualifiers":["diagnosis"],"descriptor":"Lipoma"},{"qualifiers":[],"descriptor":"Magnetic Resonance Imaging"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":["diagnosis"],"descriptor":"Spinal Cord Neoplasms"},{"qualifiers":["pathology"],"descriptor":"Thoracic Vertebrae"}],"pmid":"22610440","title":"Asymptomatic thoracic Pantopaque cyst mimicking an intradural extramedullary lipoma on MR images."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":2,"matched_diseases":["Chronic Disease","Arachnoiditis"],"diseases_with_associations":2,"total_mesh_terms":74,"total_publications_analyzed":10},"disease_associations":{"Chronic Disease":[{"pmid":"28639826","title":"Imaging Appearance of Advanced Chronic Adhesive Arachnoiditis: A Retrospective Review.","qualifiers":[]}],"Arachnoiditis":[{"pmid":"28639826","title":"Imaging Appearance of Advanced Chronic Adhesive Arachnoiditis: A Retrospective Review.","qualifiers":["diagnostic imaging","etiology"]}]}},"pmids":["38547442","36544579","30922531","30823879","29323010","28639826","27908202","27726152","23578988","22610440","22333888","21611721","20979434","18312083","18248289","18085424","17522798","16944225","16778701","16418030","12149745","11588649","11380373","11099238","11096603","11045204","10069584","9691375","9016253","8905763","8829407","8606227","7940341","8348365","8424071","1443709","1286419","1523322","1519786","1393409","1614685","1512716","1787946","1928246","2018221","1986636","1653688","2086045","2211021","1962942"]},{"indication":"Indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) [FDA Label].","drug_name":"Efmoroctocog alfa","pmids_analyzed":["40337622","39937791","39583653","39576433","39434416","39377876","39274196","39162954","39101128","39091324"],"count":46,"fetch_status":"success","publications_analyzed":[{"mesh_descriptors":[],"pmid":"40337622","title":"Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["pharmacology","therapeutic use","pharmacokinetics"],"descriptor":"Factor VIII"},{"qualifiers":["pharmacology","therapeutic use"],"descriptor":"Antibodies, Bispecific"},{"qualifiers":["pharmacology","therapeutic use"],"descriptor":"Antibodies, Monoclonal, Humanized"},{"qualifiers":["drug therapy"],"descriptor":"Hemophilia A"},{"qualifiers":[],"descriptor":"Half-Life"},{"qualifiers":["pharmacology","therapeutic use"],"descriptor":"Hemostatics"},{"qualifiers":["drug effects"],"descriptor":"Hemostasis"},{"qualifiers":["metabolism"],"descriptor":"Thrombin"}],"pmid":"39937791","title":"In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds."},{"mesh_descriptors":[],"pmid":"39583653","title":"Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["therapeutic use","pharmacokinetics","administration &amp; dosage"],"descriptor":"Factor VIII"},{"qualifiers":["drug therapy","complications"],"descriptor":"Hemophilia A"},{"qualifiers":[],"descriptor":"Adolescent"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":["prevention &amp; control","etiology"],"descriptor":"Hemorrhage"},{"qualifiers":[],"descriptor":"Half-Life"},{"qualifiers":[],"descriptor":"Drug Combinations"},{"qualifiers":[],"descriptor":"Clinical Trials, Phase III as Topic"},{"qualifiers":[],"descriptor":"Young Adult"}],"pmid":"39576433","title":"Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["drug therapy"],"descriptor":"Hemophilia A"},{"qualifiers":["administration &amp; dosage","therapeutic use","adverse effects","pharmacokinetics"],"descriptor":"Factor VIII"},{"qualifiers":[],"descriptor":"Male"},{"qualifiers":[],"descriptor":"Adult"},{"qualifiers":[],"descriptor":"Treatment Outcome"},{"qualifiers":[],"descriptor":"Adolescent"},{"qualifiers":[],"descriptor":"Half-Life"},{"qualifiers":["administration &amp; dosage","therapeutic use"],"descriptor":"Recombinant Fusion Proteins"},{"qualifiers":["prevention &amp; control","etiology"],"descriptor":"Hemorrhage"},{"qualifiers":[],"descriptor":"Child"},{"qualifiers":[],"descriptor":"Prospective Studies"},{"qualifiers":[],"descriptor":"Middle Aged"},{"qualifiers":[],"descriptor":"Female"},{"qualifiers":["therapeutic use","administration &amp; dosage"],"descriptor":"Immunoglobulin Fc Fragments"},{"qualifiers":[],"descriptor":"Young Adult"},{"qualifiers":[],"descriptor":"Child, Preschool"}],"pmid":"39434416","title":"Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study."},{"mesh_descriptors":[],"pmid":"39377876","title":"Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization."},{"mesh_descriptors":[],"pmid":"39274196","title":"Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life."},{"mesh_descriptors":[{"qualifiers":[],"descriptor":"Humans"},{"qualifiers":["pharmacokinetics","administration &amp; dosage","therapeutic use","adverse effects"],"descriptor":"Factor VIII"},{"qualifiers":[],"descriptor":"Half-Life"},{"qualifiers":["drug therapy"],"descriptor":"Hemophilia A"},{"qualifiers":["chemistry","administration &amp; dosage","pharmacokinetics"],"descriptor":"Polyethylene Glycols"},{"qualifiers":[],"descriptor":"Randomized Controlled Trials as Topic"}],"pmid":"39162954","title":"Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review."},{"mesh_descriptors":[],"pmid":"39101128","title":"Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany."},{"mesh_descriptors":[],"pmid":"39091324","title":"Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: <i>post hoc</i> analysis of phase III trials using patient-reported outcomes."}],"search_status":"success","disease_analysis":{"summary":{"unique_diseases_found":1,"matched_diseases":["Hemophilia A"],"diseases_with_associations":1,"total_mesh_terms":42,"total_publications_analyzed":10},"disease_associations":{"Hemophilia A":[{"pmid":"39937791","title":"In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds.","qualifiers":["drug therapy"]},{"pmid":"39576433","title":"Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors.","qualifiers":["drug therapy","complications"]},{"pmid":"39434416","title":"Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study.","qualifiers":["drug therapy"]},{"pmid":"39162954","title":"Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.","qualifiers":["drug therapy"]}]}},"pmids":["40337622","39937791","39583653","39576433","39434416","39377876","39274196","39162954","39101128","39091324","38266154","38149726","38043392","37753224","37720484","37587687","37563315","37553998","37243934","36908765","36735911","36398467","36188439","35699345","35696967","35390452","34851511","34743314","34590394","34368918","33868623","33867284","33780111","33664606","33500640","33377987","32107819","31850352","31214173","30670892","30071878","27487799","27462665","28924926","29144663","26149020"]}]}